READUS-PV:药物警戒中基于个例安全报告的不比例分析报告指南
READUS-PV 由34名国际专家通过开放调查、德尔菲法和共识会议制定,最终形成正文14项32条推荐、摘要4项12条推荐,用于规范基于个例安全报告的不比例分析报告,提升透明性与准确性。
要点
- READUS-PV 含正文32条推荐和摘要12条推荐,覆盖不比例分析关键报告要素。
- 指南由34名国际专家经三轮流程制定,旨在改善不比例分析报告质量。
- 采用该指南可促进不比例分析结果与其他证据的整合与解读。
核心结论
- READUS-PV 指南将支持作者、编辑、审稿人和使用者更透明、全面和准确地报告与解读不比例分析。
研究设计与样本
- 由34名来自大学、制药企业和监管机构的国际专家组成专家组,遵循三步流程制定清单:开放文本调查、在线德尔菲法、最终在线共识会议。
主要发现
- 德尔菲法第一轮有33名专家回复,第二轮有30名回复,共识会议有25名专家参加。
- 德尔菲法后保留正文60条推荐和摘要13条推荐。
- 经合并条目和在线共识会议后,READUS-PV 指南正文含14项32条推荐,摘要含4项12条推荐。
关键数值与推荐
- 正文报告清单包含14项、共32条推荐。
- 摘要报告清单包含4项、共12条推荐。
临床怎么用
- 撰写不比例分析文章或摘要时,可按 READUS-PV 正文32条和摘要12条推荐逐项报告。
- 审稿人或读者可用该清单评估不比例分析报告的透明性和完整性。
局限性
- 原文未报告指南的验证研究或实施效果评估数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIM: Disproportionality analyses using reports of suspected adverse drug reactions are the most commonly used quantitative methods for detecting safety signals in pharmacovigilance. However, their methods and results are generally poorly reported in published articles and existing guidelines do not capture the specific features of disproportionality analyses. We here describe the development of a guideline (REporting of A Disproportionality analysis for drUg Safety signal detection using individual case safety reports in PharmacoVigilance [READUS-PV]) for reporting the results of disproportionality analyses in articles and abstracts. METHODS: We established a group of 34 international experts from universities, the pharmaceutical industry, and regulatory agencies, with expertise in pharmacovigilance, disproportionality analyses, and assessment of safety signals. We followed a three-step process to develop the checklist: (1) an open-text survey to generate a first list of items; (2) an online Delphi method to select and rephrase the most important items; (3) a final online consensus meeting. RESULTS: Among the panel members, 33 experts responded to round 1 and 30 to round 2 of the Delphi and 25 participated to the consensus meeting. Overall, 60 recommendations for the main body of the manuscript and 13 recommendations for the abstracts were retained by participants after the Delphi method. After merging of some items together and the online consensus meeting, the READUS-PV guidelines comprise a checklist of 32 recommendations, in 14 items, for the reporting of disproportionality analyses in the main body text and four items, comprising 12 recommendations, for abstracts. CONCLUSIONS: The READUS-PV guidelines will support authors, editors, peer-reviewers, and users of disproportionality analyses using individual case safety report databases. Adopting these guidelines will lead to more transparent, comprehensive, and accurate reporting and interpretation of disproportionality analyses, facilitating the integration with other sources of evidence.
引用
- Fusaroli M, Salvo F, Begaud B, et al. The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement. Drug Saf. 2024. PMID: 38713346. doi:10.1007/s40264-024-01421-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。